相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia
Mohamed A. Kharfan-Dabaja et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations
Roland B. Walter et al.
LEUKEMIA (2021)
Immunotherapy in Acute Myeloid Leukemia: Where We Stand
Alessandro Isidori et al.
FRONTIERS IN ONCOLOGY (2021)
Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
Jan Philipp Bewersdorf et al.
HAEMATOLOGICA (2020)
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation
Kelly J. Norsworthy et al.
CLINICAL CANCER RESEARCH (2019)
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
Eytan M. Stein et al.
BLOOD (2019)
Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience
Chezi Ganzel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort
Maximilian Stahl et al.
BLOOD ADVANCES (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation
J. Magenau et al.
BONE MARROW TRANSPLANTATION (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
How I treat refractory and early relapsed acute myeloid leukemia
Felicitas Thol et al.
BLOOD (2015)
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
Farhad Ravandi et al.
LANCET ONCOLOGY (2015)
Prevalence, Management, and Clinical Consequences of QT Interval Prolongation During Treatment With Arsenic Trioxide
Gail J. Roboz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Tumor heterogeneity confounds and illuminates
Maria Kleppe et al.
NATURE MEDICINE (2014)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study
P. Chevallier et al.
LEUKEMIA (2011)
Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse
Saiko Kurosawa et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure
Michel Duval et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience
J Sierra et al.
BONE MARROW TRANSPLANTATION (2000)
分享论文
